Relationship between plasnna exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4867-4874

  Zamboni, William C ^a,b,c   Jung, Laura L ^c   Egorin, Merrill J ^b,c   Hamburger, Deborah R ^c   Joseph, Erin ^c   Jin, Ruzhi ^c   Strychor, Sandra ^c   Ramanathan, Ramesh K ^b,c   Eiseman, Julie L ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DRUG METABOLITE; FLUOROURACIL; RUBITECAN; 9 AMINO 20 CAMPTOTHECIN; 9-AMINO-20-CAMPTOTHECIN; 9-NITROCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLON CARCINOMA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BLOOD; CELL STRAIN HT29; COLON TUMOR; DRUG SCREENING; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; MICE; MICE, SCID; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27644469443     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0144     Document Type: Article

References (44)

1. Zamboni WC, Jung LL, Egorin MJ, et al. Phase I and pharmacologic studies of intermittently administered 9-nitrocamptothecin. Clin Cancer Res 2004;10:5058-64.
2. Schoffski P, Herr A, Vermorken JB, et al. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. Eur J Cancer 2002;38:807-13.
3. Ebrahimi B, Phan A, Yao J, et al. Phase II clinical trial of Rubitecan against advanced gastric adenocarcinoma. Proc Am Soc Clin Oncol 2002;21:596a.
4. Konstadoulakis MM, Antonakis PT, Tsibloulis BG, et al. A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001;48:417-20.
5. Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996;803:224-30.
6. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24.
7. Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta 1998;1400:301-19.
8. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
9. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998;90:505-11.
10. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999;43:454-60.
11. Drengler RL, Kuhn JG, Schaaf LJ, et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999;17:685-96.
12. Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 2000;6:2685-9.
13. Jung LL, Ramanathan R, Egorin MJ, et al. Pharmacokinetics studies of 9-nitrocamptothecin on intermittent and continuous schedules in patients with advanced cancer. Cancer Chemother Pharmacol 2004;54:487-96.
14. Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994;12:1946-54.
15. Zamboni WC, Gajjar AJ, Mandrell TD, et al. A four-hour topotecan infusion achieves cytotoxicity exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Clin Cancer Res 1998;4:2537-44.
16. Kirstein MN, Houghton PJ, Cheshire PJ, et al. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 2001;7:358-66.
17. Gounder M, Saleem A, Roychowdhury M. Metabolism of 9-nitrocamptothecin (RFS2000/9NC) to 9-aminocamptothecin (9AC) in patients and in vitro. Proc Am Assoc Cancer Res 2001;42:537.
18. Miller KD, Soule SE, Haney LG, et al. A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer. Invest New Drugs 2004;22:69-73.
19. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989;49:1465-9.
20. Stewart CF, Zamboni WC, Crom WR, et al. Topoisomerase I interactive drugs in children with cancer. Invest New Drugs 1996;14:37-47.
21. Mi Z, Burke TG. Differential interactions of camptothecin lactone and carboxylateforms with human blood components. Biochemistry 1994;33:10325-36.
22. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
23. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22.
24. Boxenbaum H. and Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983;245:R768-75.
25. Alley MC, Hollingshead MG, Pacula-Cox CM, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: efficacy and evaluations. Cancer Res 2004;64:6700-6.
26. Britten CD, Hilsenbeck SG, Eckhardt SG, et al. Enhanced antitumor activity of 6-hydroxymethylfulvene in combination with irinotecan and 5-fluorouracil in HT29 human colon tumor xenograft model. Cancer Res 1999;59:1049-53.
27. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC-707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;9:7-19.
28. Supko JG, Malspeis L. Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon post-column acidification. J Liquid Chromatograph 1992;15:3261-4.
29. Gounder MK, Sun SL, Sands H, et al. Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2004;99:63-72.
30. D'Argenio DZ, Schmuitzky A. ADAPT II user's guide: biomedical simulations resource; 1990.
31. Rowland M, Tozer T, editors. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea and Febiger; 1999.
32. Zamboni WC, Tonda ME. New designs of clinical trials. Highlights in Oncology Practice 2000;18:2-7.
33. Grever MR, Chabner BA, Shoemaker D. Cancer drug discovery and development. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practices of oncology, 5th ed. Philadelphia (PA): Lippincott-Raven; 1997:385-93.
34. Grever MR. Cancer drug screening. In: Schilsky RL, editor. Principles of antineoplastic drug development and pharmacology. New York (NY): Marcel Dekker, Inc.; 1, 1996.
35. Grever MR, Schepartz S, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622-4.
36. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-61.
37. Korn EL, Midthune D, Chen TT, et al. A comparison of two phase 1 trial designs. Stat Med 1994;13:1799-806.
38. Pitot HC, Knost JA, Mahoney MR, et al. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer 2000;89:1699-705.
39. Vokes EE, Gordon GS, Rudin CM, et al. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs 2001;19:329-33.
40. Hinz HR, Harris NJ, Natelson EA, Giovanella BC. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res 1994;54:3096-103.
41. Schoemaker NE, Mathot RAA, Schoffski P, Rosing H, Schellens JHM, Beijnen JH. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. Cancer Chemother Pharmacol 2002;50:514-7.
42. Raymond D, Campone M, Stupp R, et al. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 2002;38:1348-50.
43. Zamboni WC, Eiseman JL, Muller M, et al. Tumor disposition of carboplatin in mice bearing murine B16 melanoma is not indicative of the disposition of patients with cutaneous melanoma. Proceedings of AACR-Japanese Cancer Assoc 2004;B21.
44. Zamboni W. Use of microdialysis in preclinical and clinical development. In: Figg WD, McLeod H, editors. Handbook of pharmacokinetics and pharmacodynamics of anti-cancer drugs, 1st ed. Humana Press: Totowa, NJ; 2004.